Publication

GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity

Cell Reports 42(5): 112466, 2023 [online ahead of print]. Falk S, Petersen J, Svendsen C, Romero-Leguizamón CR, Jørgensen SH, Krauth N, Ludwig MQ, Lundø K, Roostalu U, Skovbjerg G, Gurskov Nielsen DA, Ejdrup AL, Pers TH, Dmytriyeva O, Hecksher-Sørensen J, Gether U, Kohlmeier KA, Clemmensen C

Subjects

DIO mouse CNS activation Mouse Body weight c-Fos activation Obesity Energy expenditure monitoring GLP-1 receptor Image analysis Immunohistochemistry Light sheet fluorescence microscopy (LSFM)Nicotinic acetylcholine receptor Nicotine

Share this page

Resource Library

Related resources

Whole brain distributional changes of lipidated exendin-4 peptides

Whole-brain activation signatures of weight-lowering drugs

Uncovering CNS access of lipidated exendin-4 analogues by quantitative whole-brain 3D light sheet imaging

Using whole brain imaging for development of obesity drugs

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 2650